We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Innovative Blood Test Rapidly Detects Candidemia

By LabMedica International staff writers
Posted on 19 Feb 2018
Print article
Image: The T2Candida Panel seated in the Stat Drawer of the T2Dx Instrument (Photo courtesy of T2 Biosystems).
Image: The T2Candida Panel seated in the Stat Drawer of the T2Dx Instrument (Photo courtesy of T2 Biosystems).
Candidemia is among the four most common bloodstream infections in hospitals in the USA, and Candida are the third most common cause of infections in intensive care units. The mortality rate among patients with candidemia is 40%.

Blood cultures fail to detect yeast in approximately 50% of Candida infections, and typically take two to three days for positive results to be apparent. A commercial blood test seems to perform as well as, if not better than, traditional blood cultures at detecting a type of fungal yeast infection that commonly strikes hospital patients.

Scientists at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) and their colleagues enrolled from 14 health centers 152 patients who had been diagnosed with candidemia through a blood culture. On average, it took nearly two days for the culture to identify that the patient had candidemia, and another day-and-a-half to specify which strain of Candida. Patients with Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, or Candida krusei candidemia were identified at the 14 centers using diagnostic blood cultures (dBCs). Follow-up blood samples were collected concurrently for testing by T2Candida panel (T2 Biosystems, Lexington, MA, USA) and companion cultures (cBCs).

T2Candida results were reported qualitatively for C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis. T2Candida and cBCs were positive if they detected a species present in the dBC. Median time between collection of dBC and T2Candida/cBC samples in 152 patients was 55.5 hours (range, 16.4–148.4). T2Candida and cBCs were positive in 45% (69/152) and 24% (36/152) of patients, respectively. T2Candida clinical sensitivity was 89%, as positive results were obtained in 32/36 patients with positive cBCs. Prior antifungal therapy, neutropenia, and C. albicans candidemia were independently associated with T2Candida positivity.

The authors concluded that T2Candida was sensitive for diagnosing candidemia at the time of positive blood cultures. In patients receiving antifungal therapy, T2Candida identified bloodstream infections that were missed by cBCs. T2Candida may improve care by shortening times to Candida detection and species identification compared to blood cultures, retaining sensitivity during antifungal therapy and rendering active candidemia unlikely if results are negative. The study was published on February 9, 2018, in the journal Clinical Infectious Diseases.

Related Links:
University of Pittsburgh Medical Center
T2 Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.